Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells—an in-vitro study

Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells—an in-vitro study

Abstract Background The aim of the present study was to examine the cytostatic effects of cold atmospheric plasma (CAP) on different head and neck squamous carcinoma (HNSCC) cell lines either in isolation or in combination with low dose cisplatin. The effect of CAP treatment was investigated by usin...

Full description

Bibliographic Details
Main Authors: Teresa F. Brunner, Florian A. Probst, Matthias Troeltzsch, Sabina Schwenk-Zieger, Julia L. Zimmermann, Gregor Morfill, Sven Becker, Ulrich Harréus, Christian Welz
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Head & Face Medicine
Subjects:
Cold atmospheric plasma
Head and neck cancer
Adjuvant combination therapy
Online Access:https://doi.org/10.1186/s13005-022-00322-5

Internet

https://doi.org/10.1186/s13005-022-00322-5

Similar Items